Sanofi-Aventis Sa (SNY) 33.78 -0.75

Sanofi-Aventis ADS
(SNY) 33.78 -0.75

Last Trade:	33.76	Day Range:	33.69 - 34.06
Trade Time:	06:05PM	52wk Range:	30.98 - 40.58
Prev. Close:	34.51	Market Cap:	90.54B
Open:	33.93	Div Yield:	4.82
Volume:	3760633	PE:
EPS:	0.00

The Latest On SNY

Genzyme and Isis Announce Filing of U.S. NDA for KYNAMRO in Homozygous Familial Hypercholesterolemia 5/29/12 8:02am

Amylin Shares Jump as Sanofi, Merck Sumbit Bids 5/25/12 3:15pm

FDA Considering Letting Patients Purchase Drugs Without Prescriptions 4/30/12 12:09pm

Sanofi Q1 Net Profit Jumps 50% 4/27/12 5:18am

Sanofi and Michael J. Fox Foundation Collaborate on Potential New Treatment for Parkinson's Disease 4/19/12 8:09am

From Earlier: Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP 4/5/12 7:37am

Genzyme and Isis Announce Submission of U.S. NDA for KYNAMRO in Homozygous Familial Hypercholesterolemia 3/29/12 11:01am

ImmunoCellular's Intellectual Property Steadily Increases 3/28/12 10:43pm

UPDATE: Sanofi and Regeneron Report Phase 2 Data for Potential First-in-Class Lipid-Lowering PCSK9 Antibody 3/26/12 11:32am

Benzinga's M&A Chatter for Wednesday March 21, 2012 3/21/12 7:21pm

St. Jude, Novo Nordisk and Other Health Care Stocks Worth a Look Now 3/21/12 7:20am

UPDATE: Bird Flu Found in the Netherlands 3/19/12 1:56pm

Genzyme and Isis Announce Filing of U.S. NDA for KYNAMRO in Homozygous Familial Hypercholesterolemia 5/29/12

Amylin Shares Jump as Sanofi, Merck Sumbit Bids 5/25/12

FDA Considering Letting Patients Purchase Drugs Without Prescriptions 4/30/12

Sanofi Q1 Net Profit Jumps 50% 4/27/12

Sanofi and Michael J. Fox Foundation Collaborate on Potential New Treatment for Parkinson's Disease 4/19/12

From Earlier: Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP 4/5/12

Genzyme and Isis Announce Submission of U.S. NDA for KYNAMRO in Homozygous Familial Hypercholesterolemia 3/29/12

ImmunoCellular's Intellectual Property Steadily Increases 3/28/12

UPDATE: Sanofi and Regeneron Report Phase 2 Data for Potential First-in-Class Lipid-Lowering PCSK9 Antibody 3/26/12

Benzinga's M&A Chatter for Wednesday March 21, 2012 3/21/12

St. Jude, Novo Nordisk and Other Health Care Stocks Worth a Look Now 3/21/12

UPDATE: Bird Flu Found in the Netherlands 3/19/12

ImmunoCellular's Intellectual Property Steadily Increases 3/28/12

Benzinga's M&A Chatter for Wednesday March 21, 2012 3/21/12

St. Jude, Novo Nordisk and Other Health Care Stocks Worth a Look Now 3/21/12

UPDATE: Bird Flu Found in the Netherlands 3/19/12

Benzinga's M&A Chatter for Friday March 16, 2012 3/17/12

The Peyton Manning ETF Portfolio (XLP, XLY, IYG) 3/7/12

Benzinga's M&A Chatter for Tuesday January 10, 2012 1/10/12

VIX: Volatility and the Viability of Investing in Stocks 12/9/11

Financial Breakfast: Morning News Summary for December 6, 2011 12/6/11

Mad Money Lightning Round: Cramer Dislikes Microsoft, Radioshack 12/1/11

Mad Money Lightning Round: Cramer Likes Waste Management 11/22/11

Mad Money Lightning Round: Cramer Likes Sanofi-Aventis 11/21/11

Financial Breakfast: Morning News Summary for December 6, 2011 12/6/11

Deutsche Bank Comments On Valeant's Acquisition Of Dermik 7/11/11

Benzinga's Top Upgrades (SNY, FSLR, VCLK, BLK) 5/4/11

A Peek Into The Market Before The Trading Starts 2/16/11

Jefferies Downgrades Sanofi-Aventis to Hold (SNY) 1/11/11

Jefferies Downgrades SNY To Hold 1/11/11

SNY Announces Acquisition Of BJGP 10/29/10

Sanofi Aventis Makes Hostile Offer But Willing To Negotiate 10/5/10

Citi Reiterates Buy On Sanofi-Aventis (SNY) 10/1/10

Genzyme Rejects Sanofi's Offer Twice 9/21/10

MKM Partners Expects More On The M&A Front (HTZ, CAR, DTG, ARG, APD 9/7/10

Merger Twist - S&P Upgrades Sanofi Aventis (SNY) to Buy 9/1/10

Trade SNY
NOW!

Partner Headlines

Standard Review for Isis' Kynamro - Analyst Blog 5/30/12

Mylan Launches Bonviva Generic - Analyst Blog 5/25/12

A Stock Buffett and Woodford Agree On 5/25/12

More Generic Launches for Mylan - Analyst Blog 5/24/12

Lilly's GLP-1 Agonist Delivers - Analyst Blog 5/23/12

Europe: More Is Needed 5/22/12

Medivation Files Enzalutamide NDA - Analyst Blog 5/22/12

Canada Approves Osiris' Prochymal - Analyst Blog 5/21/12

Is Sanofi-Aventis Resistance Ahead? 5/18/12

Merck KGaA's Erbitux Faces Hurdle - Analyst Blog 5/17/12

Manufacturing Facility Cleared at BMY - Analyst Blog 5/16/12

Press Releases

Genzyme Recognizes World MS Day 5/30/12 Business Wire

Genzyme and Isis Announce Filing of U.S. NDA for KYNAMRO™ (mipomersen sodium) in Homozygous Familial Hypercholesterolemia 5/29/12 Business Wire

Sanofi iBGStar® Blood Glucose Monitoring System Now Available in the U.S. 5/2/12 Newswire

Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine 5/1/12 Newswire

Sanofi CFO Jérôme Contamine Comments on Q1 2012 Results 4/27/12 Business Wire

Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received LemtradaTM* (Alemtuzumab) Compared With Rebif® in Phase III Trial 4/24/12 Business Wire

Critical Alerts For Wells Fargo, Sanofi Aventis, Delta, InterActiveCorp, and DeVry Released By InvestorsObserver 4/24/12 Newswire

Genzyme Demonstrates Depth of MS Pipeline at AAN with Results from Multiple Sclerosis Phase lll Trials 4/20/12 Business Wire

Genzyme's Biologics Support Center Achieves LEED Gold Rating for Environmentally Responsible Design 4/19/12 Business Wire

Sanofi and Michael J. Fox Foundation Collaborate on Potential New Treatment for Parkinson's Disease 4/19/12 Newswire

Genzyme and Veracyte Announce Expanded U.S. Availability of the Afirma® Thyroid FNA Analysis for Improved Thyroid Nodule Diagnosis 4/16/12 Business Wire

Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP® (aflibercept) 4/5/12 Newswire

Get the latest SNY stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Sanofi-Aventis ADS stock price.

Sanofi-Aventis ADS by YCharts

Sanofi-Aventis Sa (SNY) 33.78 -0.75

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On SNY

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social